Table 1 Review of literature about MiT TRCC since 2007
Author | Year | No of patients | Age | Sex | Size | Staging (at presentation/maximal by follow-up) | Surgery | Oncological therapy | Survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Together | TRCC | Average | Range | Over 40 | F:M | I | II | III | IV | PNE/NE | |||||||
Xp11.2 | 6p21 | Total | % | average, in mm | T1N0M0 | T2N0M0 | T3N0M0, T1-3N1M0 | T4NXM0, TXN2M0, TXNXM1 | |||||||||
Argani | 2007 | 28 | 28 | 0 | 37.2 | 22 - 78 | 7 | 25.0% | 22 : 6 | 6.8 | 9 | 3 | 2 | 14 | UK | in 1 case, imuno- and RT | 6:3 malignant vs bening course |
Rais-Bahrami | 2007 | 1 | 1 | 6 | NA | 0 | 0.0% | 0 : 1 | 1.5 | 1 | 0/1 | TKI, progression, death in 8 ms | generalisation 17 ys later | ||||
LaGrande | 2007 | 1 | 1 | 63 | NA | 1 | 100.0% | 1 : 0 | 3 | 1 | 2 ys without sign of recurrence | ||||||
Franzini | 2007 | 1 | 1 | 79 | NA | 1 | 100.0% | 0 : 1 | 12 | 1 | none | metastases in 1 m | |||||
Hora | 2008 | 2 | 2 | 0 | 57 | 34-80 | 1 | 50.0% | 1:1 | 46 | 1 | 1 | none | one died 1 mfor generalisation | |||
Camparo | 2008 | 3423 | 29 | 2 | 24.6 | 0.9-64 | 3 | 9.7% | 18:13 | 69 | 12 | 2 | 7 | 10 | 4/27 | FU 29.5 ms, 21 NoR, 5 died, 3 metastases, 2 lost for FU | |
Hora | 2009 | 15000 | 0 | 3 | 28.3 | 22-39 | 0 | 0.0% | 2:01 | 62 | 2 | 1 | 2/1 | none | no recurrence | ||
Suárez-Vilela | 2009 | 1 | 0 | 1 | 22.0 | 22 | 0 | 0.0% | 0 : 1 | large | 1 | 0/1 | no recurrence | ||||
Koie | 2009 | 1 | 1 | 28.0 | NA | 0 | 0.0% | 0 : 1 | 85 | 1 | 0/1 | excision of local recurrence, cytokins | died in 24 ms | ||||
Armah | 2009 | 1 | 1 | 26.0 | NA | 0 | 0.0% | 1 : 0 | 75 | 1 | 1/0 | none | pregnant, 27 ms without recurrence | ||||
Kuroda | 2010 | 1 | 1 | 73.0 | 1 | 100.0% | 1 : 0 | 20 | 1 | Unknown | |||||||
Jing | 2010 | 1 | 1 | 12.0 | NA | 0 | 0.0% | 0 : 1 | 60 | 1 | Ch, RT | Alive in 17 ms | |||||
Choueiri | 2010 | 15 | 15 | 41.0 | 18-65 | UK | UK | 12:3 | UK | 2 | 1 | 8 | 8 | 0/12 | VEGF-targeted therapy | ||
Ishihara | 2011 | 1 | 1 | 45.0 | NA | 1 | 100.0% | 0 : 1 | 70 | 1 | 0/1 | ChT, RT, temsirolimus | in 8 ms generalisation | ||||
Liu | 2011 | 1 | 1 | 27.0 | NA | 0 | 0.0% | 1 : 0 | 100 | 1 | 0/1 | metastasectomy, gemcitabin, sunitinib | partial response to sunitinib | ||||
Nelius | 2011 | 1 | 1 | 19.0 | NA | 0 | 0.0% | 0 : 1 | 115 | 1 | 1/0 | ChT, sorafenib, temsirolimus, bavacizumab, RT | died in 3 ms | ||||
Numakura | 2011 | 1 | 1 | 43.0 | NA | 1 | 100.0% | 1 : 0 | 100 | 1 | 1/0 | sunitinib - PR for over 3years | lung metatases 2 ys from surgery | ||||
Kato | 2011 | 1 | 1 | 0 | 18.0 | 18 | 0 | 0.0% | 0:1 | 41 | 1 | 0/1 | none | UK | |||
Klatte | 2012 | 848 | 2 | 0 | NA | 5 and 42 | 1 | 50.0% | 1 : 1 | 100 | 0 | 1 | 0 | 1 | 0/2 | dendritics cells and interferon-alfa-2a (CR) | 4.5 and 8 ms |
Morii | 2012 | 1 | 1 | 0 | 38.0 | 38 | 0 | 0.0% | 1 : 0 | 75 | 0 | 0 | 0 | 1 | 1/0 | imunotherapy, sunitinib, sorafenib, mTOR I | died in 16 ms |
Rao | 2012 | 7 | 0 | 7 | 30.6 | 21-37 | 0 | 0.0% | 4 : 3 | 51 | 5 | 2 | 0 | 0 | UK | none | NED in any case |
Inamura | 2012 | 200 | 0 | 3 | 47.0 | 37-57 | 2 | 66.7% | 0:3 | UK | UK | UK | UK | UK | UK | one aggresive course | |
Arnoux | 2012 | 170 | 4 | 0 | UK | UK | 4 | 100.0% | UK | UK | 0 | 0 | 1 | 3 | 4/0 | UK | one died, 3 others progression |
Dang | 2012 | 9 | 9 | 0 | 29.6 | 18-45 | 1 | 11.1% | 3:6 | 58 | UK | UK | UK | UK | 5-Mar | ChT 4 cases, RT 2 cases, 2 excision of retroperitoneal recurrence | 2 died, 1 metastatic disease, 2 local recurrence |
Komai | 2013 | 443 | 7 | 0 | 42.0 | 15-59 | 5 | 71.4% | 3:4 | 83 | 3 (Hora et al. 2008) | 1 (0) | 0 Srigley et al. (2013) | 2 Klatte et al. (2012) | 0/7 | UK | 5 of 7 (71.4%) generalisation |
Gaillot-Durand | 2013 | 92 | 2 | 0 | UK | UK | UK | UK | UK | UK | UK | UK | UK | UK | UK | UK | UK |
Together | 20255 | 110 | 17 | 29 | 22.8% | 35 | 14 | 21 | 40 | ||||||||
127 | 32% | 13% | 19% | 36% | |||||||||||||